Technical Analysis for ESPR - Esperion Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | 3.11% | |
| Crossed Above 200 DMA | Bullish | 3.11% | |
| MACD Bullish Signal Line Cross | Bullish | 3.11% | |
| Up 3 Days in a Row | Strength | 3.11% | |
| 20 DMA Resistance | Bearish | 15.58% | |
| NR7 | Range Contraction | 15.58% | |
| NR7-2 | Range Contraction | 15.58% | |
| 20 DMA Resistance | Bearish | 17.22% | |
| MACD Bearish Signal Line Cross | Bearish | 17.22% | |
| Calm After Storm | Range Contraction | 17.22% |
| Alert | Time |
|---|---|
| Rose Above Upper Bollinger Band | about 1 hour ago |
| Up 3% | about 1 hour ago |
| Upper Bollinger Band Resistance | about 2 hours ago |
| 60 Minute Opening Range Breakout | about 2 hours ago |
| Rose Above Previous Day's High | about 2 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/07/2024
Esperion Therapeutics, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of therapies for the treatment of patients with low-density lipoprotein cholesterol and other cardiometabolic risk factors. Its products include ETC-1002, an oral molecule therapy that is in Phase IIa clinical trials to treat lipid and carbohydrate metabolic pathways; ESP41091, which is in pre-clinical trials for type 2 diabetes and obesity treatment; and 4WF, a synthetic therapy that is in pre-clinical trials to reverse the deleterious effects of atherosclerosis. The company is based in Plymouth, Michigan.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Diabetes Obesity Lipid Cardiology Cholesterol Lipoprotein Low Density Lipoprotein Atherosclerosis Gabaa Receptor Positive Allosteric Modulators Niacin
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Diabetes Obesity Lipid Cardiology Cholesterol Lipoprotein Low Density Lipoprotein Atherosclerosis Gabaa Receptor Positive Allosteric Modulators Niacin
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.4 |
| 52 Week Low | 1.1601 |
| Average Volume | 3,995,037 |
| 200-Day Moving Average | 2.22 |
| 50-Day Moving Average | 2.00 |
| 20-Day Moving Average | 2.18 |
| 10-Day Moving Average | 2.28 |
| Average True Range | 0.17 |
| RSI (14) | 60.47 |
| ADX | 27.45 |
| +DI | 34.31 |
| -DI | 19.87 |
| Chandelier Exit (Long, 3 ATRs) | 2.10 |
| Chandelier Exit (Short, 3 ATRs) | 2.37 |
| Upper Bollinger Bands | 2.48 |
| Lower Bollinger Band | 1.89 |
| Percent B (%b) | 0.89 |
| BandWidth | 26.77 |
| MACD Line | 0.08 |
| MACD Signal Line | 0.08 |
| MACD Histogram | 0.0083 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.63 | ||||
| Resistance 3 (R3) | 2.62 | 2.53 | 2.59 | ||
| Resistance 2 (R2) | 2.53 | 2.48 | 2.54 | 2.58 | |
| Resistance 1 (R1) | 2.47 | 2.44 | 2.50 | 2.48 | 2.57 |
| Pivot Point | 2.39 | 2.39 | 2.40 | 2.39 | 2.39 |
| Support 1 (S1) | 2.33 | 2.33 | 2.36 | 2.34 | 2.25 |
| Support 2 (S2) | 2.24 | 2.30 | 2.25 | 2.24 | |
| Support 3 (S3) | 2.18 | 2.24 | 2.23 | ||
| Support 4 (S4) | 2.19 |
